Investigational drug therapies for treatment of multiple sclerosis

Multiple Sclerosis

Volumn 2, Issue 2, 1996, Pages 66-77

  Panitch, Hillel S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Demyelinating disease; Immunoregulation; Immunosuppression; Interferons; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; IMMUNOLOGICAL ADJUVANT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; INTERFERON BETA-1B; MONOCLONAL ANTIBODY; NEW DRUG; RECOMBINANT PROTEIN;

HUMAN; IMMUNOLOGY; MULTIPLE SCLEROSIS; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS;

EID: 0030224504     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600200202     Document Type: Article

References (21)

1. Antel JP, Arnason BGW. (1991) Demyelinating diseases. In: Wilson JD, et al (eds.) Harrison's Principles of Internal Medicine. 12th ed. McGraw-Hill: New York: chapter 356.
2. Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667.
3. Noseworthy JH et al. (1994) The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44: 16-20.
4. Whitaker JN, McFarland HF, Rudge P, Reingold SC. (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1: 37-47.
5. Whitaker JN. (1994) Rationale for immunotherapy in multiple sclerosis. Ann Neurol 36 (Suppl): S103-S107.
6. Arnason BGW. (1993) Interferon beta in multiple sclerosis. Neurology 43: 641-643 (Editorial).
7. Arnason BGW, Reder AT. (1994) Interferons and multiple sclerosis. Clin Neuropharmacol 17: 495-547.
8. Selmaj K, et al. (1991) Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol 147: 1522-1529.
9. Hirsch RL, Panitch HS, Johnson KP. (1985) Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol 5: 386-389.
10. Panitch HS, Hirsch RL, Haley AS, Johnson KP. (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1: 893-895.
11. Panitch HS, Hirsch RL, Schindler J, Johnson KP. (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 37: 1097-1102.
12. Ling PD, Warren MK, Vogel SN. (1985) Antagonistic effect of interferon β on the interferon-γ-induced expression of 1a antigen in murine macrophages. J Immunol 135: 1857-1863.
13. Barna BP, et al. (1989) Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol 23: 45-53.
14. Hartung H-P, et al. (1995) Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology 45 (Suppl 6): S22-S32.
15. Selmaj KW, Raine CS. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346.
16. Olsson T. (1995) Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology 45 (Suppl 6): S11-S15.
17. Schauf CL, Davis FA. (1974) Impulse conduction in multiple sclerosis: a theoretical basis for modification by temperature and pharmacological agents. J Neurol Neurosurg Psychiatry 37: 152-161.
18. Rasminsky M. (1973) The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol 28: 287-292.
19. Waxman SG. (1982) Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med 306: 1529-1533.
20. Compston A. (1994) Future prospects for the management of multiple sclerosis. Ann Neurol 36 (Suppl): S146-S150.
21. Bever CT Jr. (1994) The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 36 (Suppl): S118-S121.